The new AUC for Imaging Evaluation of Biochemical Recurrence (BCR) of Prostate Cancer After Definitive Primary Treatment addresses several clinical scenarios for nuclear medicine. To improve utilization and guide providers to use nuclear medicine for prostate cancer in a more appropriate way, the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Nuclear Medicine (EANM), the American Society of Clinical Oncology (ASCO), the American College of Nuclear Medicine (ACNM), the American Society for Radiation Oncology (ASTRO), the American Urological Association (AUA), the American College of Physicians (ACP), the American College of Radiology (ACR), and the World Molecular Imaging Society (WMIS) have collaboratively developed criteria for the appropriate use imaging technologies to aid referring medical practitioners in the appropriate use of imaging for the diagnostic evaluation of patients with BCR of prostate cancer after definitive primary treatment. This AUC has been endorsed by the American College of Nuclear Medicine (ACNM) and the European Association of Nuclear Medicine (EANM).
SNMMI assembled an autonomous Prostate Cancer Imaging Workgroup consisting of experts in the field of nuclear medicine with substantive knowledge in the use of imaging evaluation of BCR of prostate cancer after definitive primary treatment to review the scientific literature and develop consensus recommendations for the clinical use of this technology. The Oregon Health Science University's (OHSU) Evidence-based Practice Center (EPC) conducted a systematic review of existing evidence based on the scope and parameters the Prostate Cancer Imaging Workgroup put together, which they used to make their recommendations for clinical use.
To view the development process, please click the following link: SNMMI AUC Development Process.